Bla Bla - PDFSEARCH.IO - Document Search Engine

Bla Bla
Results: 1118

#	Item
931	New Drug Application (NDA) and Biologic License Application (BLA) Efficacy Supplement Calendar Year Approvals: 2011 Add to Reading List Source URL: www.fda.gov Language: English Chemistry Research Organic chemistry Piperazines Pharmacology New Drug Application FDA Fast Track Development Program Aripiprazole Clinical trial Food and Drug Administration Clinical research Pharmaceutical industry
932	CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012 Selection Criteria: User Response: Start Date: [removed] Add to Reading List Source URL: www.fda.gov Language: English Benzamides Piperazines Orphan drugs Organofluorides Kidney cancer Ponatinib Omacetaxine mepesuccinate Chronic myelogenous leukemia Renal cell carcinoma Medicine Oncology Chemistry
933	New Drug Application (NDA) & Biologic License Application (BLA) Efficacy Supplements (CY2010) Add to Reading List Source URL: www.fda.gov Language: English Amines Organochlorides Pharmaceutical industry Eli Lilly and Company Alcohols New Drug Application Darunavir Dasatinib Duloxetine Chemistry Organic chemistry Pharmacology
934	CDER New Molecular Entity (NME)/ New BLA Calendar Year Approvals As of December 31, 2009 Add to Reading List Source URL: www.fda.gov Language: English Immunosuppressants Centocor Ustekinumab Celgene Febuxostat Pharmacology Chemistry Organic chemistry Carboxylic acids
935	DEPARTMENT OF THE NAVY UNITED STATES NAVAL ACADEMY 121 BLA.KE ROAD ANNAPOLIS MARYLAND 21402·1300 Add to Reading List Source URL: www.usna.edu Language: English - Date: 2014-03-28 09:32:25 Military Order of the Dragon Government of Oklahoma Governor of Oklahoma Heights Community Council
936	Summary Basis for Regulatory Action Date From Subject BLA Supplement# Applicant Add to Reading List Source URL: www.fda.gov Language: English Coagulation system Acute phase proteins Gross pathology Fibrinolysis Fibrin glue Coagulation Thrombin Aprotinin Seroma Blood Anatomy Biology
937	Summary Basis for Regulatory Action Date From Subject BLA Supplement# Applicant Add to Reading List Source URL: www.fda.gov Language: English Evaluation methods Pharmacology Research Scientific method Neurological disorders Clinical trial Placebo-controlled study Multifocal motor neuropathy Virus Science Clinical research Design of experiments
938	Assessing User Fees; PMA Supplement Definitions, Modular PMA Fees, BLA and Efficacy Supplement Definitions Bundling Multiple Devices in a Single Application and Fees for Combinations PRoducts; Guidance for Industry and F Add to Reading List Source URL: www.fda.gov Language: English Technology Investigational Device Exemption Premarket approval Federal Food Drug and Cosmetic Act Medical device Center for Devices and Radiological Health Title 21 of the Code of Federal Regulations Clinical trial Humanitarian Device Exemption Food and Drug Administration Medicine Health
939	Assessing User Fees; PMA Supplement Definitions, Modular PMA Fees, BLA and Efficacy Supplement Definitions Bundling Multiple Devices in a Single Application and Fees for Combinations PRoducts; Guidance for Industry and F Add to Reading List Source URL: www.fda.gov Language: English Technology Investigational Device Exemption Premarket approval Federal Food Drug and Cosmetic Act Medical device Center for Devices and Radiological Health Title 21 of the Code of Federal Regulations Clinical trial Humanitarian Device Exemption Food and Drug Administration Medicine Health
940	pBabe H6-PDGFR TM-VACHT LTR1 CDS bla (AmpR) Misc. signal Start Add to Reading List Source URL: www.mbic.cmu.edu Language: English - Date: 2011-09-26 15:29:06

UPDATE